![Still image of ZORYVE (roflumilast) cream on a skin cube from a plaque psoriasis drug MOA animation.](https://axs3d.com/wp-content/uploads/2023/08/axs-studio-medical-animation-psoriasis-zoryve-moa-02-1024x576.jpg)
Osteoporosis Animation: Sclerostin Inhibitor MOA
Created for Biopharmaceutical client
Link copied!
![axs-studio-medical-animation-osteoporosis-drug-MOA-01](https://axs3d.com/wp-content/plugins/tia/img/bg-placeholder.jpg)
Bone tissue cube illustrating the process of bone formation and resorption. Shown are osteoblasts, osteoclasts and osteocytes. Sclerostin molecule. ©2017 Amgen, Inc. All rights reserved.
![axs-studio-medical-animation-osteoporosis-drug-MOA-02](https://axs3d.com/wp-content/plugins/tia/img/bg-placeholder.jpg)
A comparison between normal and compromised osteoporotic bone structure. The blue regions indicate eroded surfaces that can lead to a weakness in cortical and trabecular bone. ©2017 Amgen, Inc. All rights reserved.
![axs-studio-medical-animation-osteoporosis-drug-MOA-03](https://axs3d.com/wp-content/plugins/tia/img/bg-placeholder.jpg)
Close up of bone tissue cube illustrating the process of bone formation and resorption. Shown are osteoblasts, osteoclasts and osteocytes. The Evenity (romosozumab) molecule is seen bound to sclerostin. ©2017 Amgen, Inc. All rights reserved.
The project
This medical animation demonstrates the mechanism of action (MOA) of a novel bone forming agent that inhibits the protein sclerostin to promote gains in bone mass. We created an isolated bone cube and visually distinct cell groups to clearly illustrate the complementary processes of bone formation and bone resorption in osteoporosis and its treatment.
Created for
Biopharmaceutical client